Hans-Peter Guler
Corporate Officer/Principal en Syneos Health NC LLC .
Perfil
Hans-Peter Guler is a Senior VP-Clinical Development Endocrine at Syneos Health NC LLC.
He previously worked as a Vice President-Clinical Sciences at Regeneron Pharmaceuticals, Inc. and as a Chief Medical Officer at Phenomix Corp.
He holds a doctorate degree from the University of Zurich.
Cargos activos de Hans-Peter Guler
Empresas | Cargo | Inicio |
---|---|---|
Syneos Health NC LLC
Syneos Health NC LLC Miscellaneous Commercial ServicesCommercial Services Syneos Health LLC operates therapeutically focused global contract research organization. It provides pharma and biotech services. The firm specializes in the hematology, immunology and inflammation infectious diseases, oncology, ophthalmology, cardiovascular, CNS analgesia, CNS neurology, CNS psychiatry, endocrinology, and gastroenterology and hepatology. The company was founded by Kenneth A. Selzer in 1985 and is headquartered in Raleigh, NC. | Corporate Officer/Principal | 29/09/2010 |
Antiguos cargos conocidos de Hans-Peter Guler.
Empresas | Cargo | Fin |
---|---|---|
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Director Técnico/Científico/I+D | 28/10/2010 |
REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formación de Hans-Peter Guler.
University of Zurich | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
REGENERON PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
Syneos Health NC LLC
Syneos Health NC LLC Miscellaneous Commercial ServicesCommercial Services Syneos Health LLC operates therapeutically focused global contract research organization. It provides pharma and biotech services. The firm specializes in the hematology, immunology and inflammation infectious diseases, oncology, ophthalmology, cardiovascular, CNS analgesia, CNS neurology, CNS psychiatry, endocrinology, and gastroenterology and hepatology. The company was founded by Kenneth A. Selzer in 1985 and is headquartered in Raleigh, NC. | Commercial Services |
- Bolsa de valores
- Insiders
- Hans-Peter Guler